Were Hedge Funds Right About ASLAN Pharmaceuticals Limited (ASLN)?
Is ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) has experienced an increase in hedge fund interest recently. ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) was in 18 hedge funds’ portfolios at the end of March. The all time high for this statistic was previously 5. This means the bullish number of hedge fund positions in this stock currently sits at its all time high. There were 5 hedge funds in our database with ASLN p
Were Hedge Funds Right About CymaBay Therapeutics Inc (CBAY)?
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Is CBAY A Good Stock To Buy Now?
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Share:
– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting –
– Board of Directors intends to appoint Dr. Albert Cha to serve as Chair after 2021 AGM –
COPENHAGEN, Denmark, Dec. 14, 2020 (GLOBE NEWSWIRE) Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced a planned board transition at the 2021 Annual General Meeting (AGM).
Michael Wolf Jensen informed the Board of Directors (the Board) that he will not stand for re-election to the Board at the next Annual General Meeting. Mr. Jensen will continue in his role as Senior Vice President (SVP) and Chief Legal Officer of Ascendis. The Board intends to appoint current board member, Dr. Albert Cha, to serve as Chair upon expiration of Mr. Jensen s term. Mr. Jensen has served as Director and Chair of Ascendis Pharma since January 20